Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
New Scientist21h
Weight-loss medications may also ease chronic pain
Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising ...
pulmonologyadvisor2h
GLP-1 Drug Shortages: How Do They Affect Patients With Diabetes?
GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
Woman's World on MSN21h
Mimic Ozempic's Weight Loss Effects Naturally With a Keto-Based Diet
Everyone is raving about the slimming power of semaglutide medications like Ozempic and Wegovy, which experts say is as ...
kpvi9h
More Evidence That GLP-1 Meds Curb Alcohol Abuse
The diabetes meds in question are called GLP-1 RAs (sometimes abbreviated as GLP-1s). They include diabetes meds like ...